CA2780611A1 - Pharmaceutical combination of prostaglandin compound and nsaid for the treatment of glaucoma and ocular hypertension - Google Patents

Pharmaceutical combination of prostaglandin compound and nsaid for the treatment of glaucoma and ocular hypertension Download PDF

Info

Publication number
CA2780611A1
CA2780611A1 CA2780611A CA2780611A CA2780611A1 CA 2780611 A1 CA2780611 A1 CA 2780611A1 CA 2780611 A CA2780611 A CA 2780611A CA 2780611 A CA2780611 A CA 2780611A CA 2780611 A1 CA2780611 A1 CA 2780611A1
Authority
CA
Canada
Prior art keywords
effective amount
composition
pharmaceutically acceptable
ocular hypertension
glaucoma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2780611A
Other languages
English (en)
French (fr)
Inventor
Rajesh Kshirsagar
Chandrashekar Kadam
Pravin KAMBLE
SM Mudda
Original Assignee
Micro Labs Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Micro Labs Ltd filed Critical Micro Labs Ltd
Publication of CA2780611A1 publication Critical patent/CA2780611A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA2780611A 2009-11-11 2010-11-01 Pharmaceutical combination of prostaglandin compound and nsaid for the treatment of glaucoma and ocular hypertension Abandoned CA2780611A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN2761CH2009 2009-11-11
IN2761/CHE/2009 2009-11-11
PCT/IN2010/000717 WO2011058579A1 (en) 2009-11-11 2010-11-01 Pharmaceutical combination of prostaglandin compound and nsaid for the treatment of glaucoma and ocular hypertension

Publications (1)

Publication Number Publication Date
CA2780611A1 true CA2780611A1 (en) 2011-05-19

Family

ID=43587393

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2780611A Abandoned CA2780611A1 (en) 2009-11-11 2010-11-01 Pharmaceutical combination of prostaglandin compound and nsaid for the treatment of glaucoma and ocular hypertension

Country Status (10)

Country Link
US (1) US20120232140A1 (enExample)
EP (1) EP2498768A1 (enExample)
JP (1) JP2013510845A (enExample)
CN (1) CN102711748A (enExample)
AU (1) AU2010317390A1 (enExample)
BR (1) BR112012010936A2 (enExample)
CA (1) CA2780611A1 (enExample)
MX (1) MX2012005447A (enExample)
RU (1) RU2012124216A (enExample)
WO (1) WO2011058579A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2852995C (en) * 2011-10-12 2016-03-29 Bausch & Lomb Incorporated Ocular composition containing bromfenac with increased bioavailability
JP6185725B2 (ja) * 2012-02-24 2017-08-23 わかもと製薬株式会社 水性医薬組成物
WO2021001806A1 (en) * 2019-07-04 2021-01-07 Ocular Discovery Ltd. Stable dipyridamole formulations with reduced impurities

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5631287A (en) * 1994-12-22 1997-05-20 Alcon Laboratories, Inc. Storage-stable prostaglandin compositions
US6011062A (en) * 1994-12-22 2000-01-04 Alcon Laboratories, Inc. Storage-stable prostaglandin compositions
US6646001B2 (en) * 1997-12-19 2003-11-11 Alcon Manufacturing, Ltd. Use of non-steroidal anti-inflammatory agents in combination with prostaglandin FP receptor agonists to treat glaucoma and ocular hypertension
PE20020146A1 (es) * 2000-07-13 2002-03-31 Upjohn Co Formulacion oftalmica que comprende un inhibidor de ciclooxigenasa-2 (cox-2)
WO2004064828A1 (ja) * 2003-01-21 2004-08-05 Senju Pharmaceutical Co., Ltd. ２−アミノ−３−(４−ブロモベンゾイル)フェニル酢酸含有水性液剤
US20050119262A1 (en) * 2003-08-21 2005-06-02 Pharmacia Corporation Method for preventing or treating an optic neuropathy with a cox-2 inhibitor and an intraocular pressure reducing agent

Also Published As

Publication number Publication date
CN102711748A (zh) 2012-10-03
EP2498768A1 (en) 2012-09-19
WO2011058579A1 (en) 2011-05-19
JP2013510845A (ja) 2013-03-28
MX2012005447A (es) 2012-07-20
RU2012124216A (ru) 2013-12-20
US20120232140A1 (en) 2012-09-13
BR112012010936A2 (pt) 2017-10-17
AU2010317390A1 (en) 2012-06-07

Similar Documents

Publication Publication Date Title
US12133842B2 (en) Stable preservative-free mydriatic and anti-inflammatory solutions for injection
AU2008354558B2 (en) Stable ophthalmic formulations
US9012503B2 (en) Ophthalmic composition
US10179127B2 (en) Pharmaceutical formulations comprising a pyridylaminoacetic acid compound
US8518996B2 (en) Aqueous intraocular penetration-promoting eye drop
AU2013361579B2 (en) LFA-1 inhibitor formulations
US20130267591A1 (en) Novel ophthalmic compositions
US20120232140A1 (en) Pharmaceutical combination of prostaglandin compound and nsaid for the treatment of glaucoma and ocular hypertension
US20220354784A1 (en) Stable latanoprost compound ophthalmic compositions
US11564931B2 (en) Low benzalkonium chloride bimatoprost ophthalmic compositions with effective penetration and preservation properties
CA2911983A1 (en) Stable bromfenac solution
ES2731754T3 (es) Composición farmacéutica oftalmica que contiene un inhibidor de anhidrasa carbónica y método para la preparación de la misma
US20220370396A1 (en) Methods for modulating conditions of the eye using novel latanoprost compound ophthalmic compositions
US20120232139A1 (en) Composition for ocular topical administration treatment ocular hypertension and glaucoma
HK1178446A1 (en) Polymeric delivery system for a nonviscous prostaglandin-based solution without preservatives
HK1178446B (en) Polymeric delivery system for a nonviscous prostaglandin-based solution without preservatives
HK1201464B (en) Polymeric delivery system for a nonviscous prostaglandin-based solution without preservatives
JP2011037736A (ja) 眼科用水性組成物
WO2020197816A1 (en) Anesthetic composition and method of anesthetizing the eye

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20141103